Back to Search
Start Over
Use of Intravenous Minocycline for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) and Resistant Gram-Negative Organisms
- Source :
- Infectious Diseases in Clinical Practice. 22:26-31
- Publication Year :
- 2014
- Publisher :
- Ovid Technologies (Wolters Kluwer Health), 2014.
-
Abstract
- BackgroundMinocycline (MINO), a tetracycline antibiotic, has been available since the 1960s. The intravenous (IV) formulation was withdrawn from the market in 2005 but was reintroduced in the US market in 2009. The drug has potent activity against methicillin-resistant Staphylococcus aureus (MRSA) a
- Subjects :
- Microbiology (medical)
Drug
medicine.medical_specialty
medicine.drug_class
business.industry
media_common.quotation_subject
Tetracycline antibiotics
Minocycline
biochemical phenomena, metabolism, and nutrition
Tertiary care hospital
bacterial infections and mycoses
medicine.disease_cause
Methicillin-resistant Staphylococcus aureus
Microbiology
Infectious Diseases
Staphylococcus aureus
medicine
Intensive care medicine
business
health care economics and organizations
medicine.drug
media_common
Subjects
Details
- ISSN :
- 10569103
- Volume :
- 22
- Database :
- OpenAIRE
- Journal :
- Infectious Diseases in Clinical Practice
- Accession number :
- edsair.doi...........2a443df206415a1a2a785de49d9dadbb
- Full Text :
- https://doi.org/10.1097/ipc.0b013e31828bbb82